Amgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations

Amgen to Receive Worldwide Exclusive License to Arrowhead's RNAi ARC-LPA Program Amgen Receives Exclusive License Option to RNAi Therapy for Undisclosed Cardiovascular Target Arrowhead to Receive $56.5 Million in Upfront Payments and Initial Equity Investment and up to an Additional $617 Million in Potential Milestone and Equity Payments Arrowhead Will Hold a Webcast Today at 9 a.m. ET

Amgen - Investors - RSS Content